Literature DB >> 9773248

Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

P E Spronk1, H Bootsma, C G Kallenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9773248     DOI： 10.1007/BF02737631

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  39 in total

1.  Longitudinal studies of anti-DNA antibody levels in SLE.

Authors:  R W Lightfoot; P B Redecha; N Levesanos
Journal:  Scand J Rheumatol Suppl       Date:  1975

2.  STEROID THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON IMMUNOLOGIC CONSIDERATIONS.

Authors:  K LANGE; R ORES; W STRAUSS; M WACHSTEIN
Journal:  Arthritis Rheum       Date:  1965-04

3.  Reduction in circulating dsDNA antibody titer after administration of LJP 394.

Authors:  M H Weisman; H G Bluestein; C M Berner; H A de Haan
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

4.  Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al.

Authors:  C G Kallenberg; H Bootsma; P E Spronk; E J ter Borg; R H Derksen; L Kater
Journal:  Arthritis Rheum       Date:  1997-02

5.  The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation.

Authors:  H Bootsma; P E Spronk; E J Ter Borg; E J Hummel; G de Boer; P C Limburg; C G Kallenberg
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

6.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

7.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

Review 8.  Anti-dsDNA: choice of assay in relation to clinical value.

Authors:  R J Smeenk; H G van den Brink; K Brinkman; R M Termaat; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

9.  Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).

Authors:  W Lloyd; P H Schur
Journal:  Medicine (Baltimore)       Date:  1981-05       Impact factor: 1.889

10.  Prevention of relapses in systemic lupus erythematosus.

Authors:  H Bootsma; P Spronk; R Derksen; G de Boer; H Wolters-Dicke; J Hermans; P Limburg; F Gmelig-Meyling; L Kater; C Kallenberg
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321
View more
  4 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus.

Authors:  Loes van den Berg; Hans Nossent; Ole Rekvig
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

3.  Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity.

Authors:  Ehud Paz; Muhammed Adawi; Idit Lavi; Yehuda Mussel; Reuven Mader
Journal:  Rheumatol Int       Date:  2007-02-16       Impact factor: 2.631

4.  Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: A cross-sectional analysis.

Authors:  Alexander Chen; Hung-Ta Chen; Yih-Hsiou Hwang; Yi-Tsun Chen; Ching-Hsi Hsiao; Hung-Chi Chen
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.